Pharmidex Exhibiting at ERS International Congress 2018
September 12, 2018

Pharmidex will be exhibiting at the up coming ERS conference.

ERS International Congress Paris 2018. 



The conference will be taking place from the 16th to the 19th of September. Please Feel free to visit the Pharmidex team at booth K.38 which is located on the 1st floor of the congress center.


Covering key topics in respiratory medicine from across the spectrum of disease areas including TB, lung cancer, chronic and acute respiratory failure, sleep breathing disorders, interstitial lung diseases, pneumonia, cystic fibrosis, COPD and asthma, amongst others, the Congress programme is set to deliver the best advances in both science and education.


This Congress will specifically highlight the importance of environment in respiratory health and focus on the need to personalise medicine in the respiratory arena. Special attention will also be paid to our interactions with microorganisms in our environment as well as those that live in peace within our organism.


We look forward to welcoming you to the ERS International Congress where we will continue our mission to promote lung health and drive standards in respiratory medicine, in close partnership with national societies, patient organisations, and various institutions all over Europe and beyond.

May 5, 2026
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.
May 1, 2026
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. 🗓️ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. 🔗 https://lnkd.in/eZ6vVjgN
April 29, 2026
We’re pleased to introduce the Pharmidex Senior Management Team (SMT), bringing together expertise across drug discovery, bioanalysis, DMPK, and translational science: 🔹 Alix Hampson 🔹 Dr Mansoor Chishty 🔹 Prof Mo Alavijeh (FRSC, FRSM) 🔹 Dr Martin Barrett 🔹 Dr Stephen Mitchell 🔹 Ash Alavijeh Collectively, the team brings 150+ years of combined experience, supporting programmes from discovery through to the clinic and beyond. We’ve also seen firsthand how similar pieces, in the hands of our 400+ innovative clients, can be combined to unlock real impact for patients. To mark the occasion, we’ve reimagined our SMT in LEGO style 🧱 Much like LEGO: • Great things are built step by step • Every piece has a purpose • The best outcomes come from creativity, collaboration, and continuous evolution At Pharmidex, it’s about bringing the right pieces together, to build smarter solutions and better outcomes.
More Posts